Učitavanje...

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Surg Case Rep
Glavni autori: Imanishi, Naoko, Yoneda, Kazue, Taira, Akihiro, Ichiki, Yoshinobu, Sato, Naoko, Hisaoka, Masanori, Tanaka, Fumihiro
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2018
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/
https://ncbi.nlm.nih.gov/pubmed/29524063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!